A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease
Julia Xu(University of Pittsburgh), Swee Lay Thein(National Heart Lung and Blood Institute), Emily B. Dunkelberger(National Institutes of Health), Ingrid Frey(National Institutes of Health), Anna Conrey(National Heart Lung and Blood Institute), Laurel A. Menapace(National Institutes of Health), Maureen Lundt(National Institutes of Health), Heidi Mangus(Agios Pharmaceuticals (United States)), Eveline Gwaabe(National Institutes of Health), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Kristen E. Glass(National Institutes of Health), Peter Hawkins(Agios Pharmaceuticals (United States)), Laxminath Tumburu(National Heart Lung and Blood Institute), Quan Li(National Institutes of Health), Neal Jeffries(National Institutes of Health), William A. Eaton(National Institutes of Health), Charles Kung(Agios Pharmaceuticals (United States)), Timothy Lequang(National Institutes of Health), Varsha Iyer(Agios Pharmaceuticals (United States)), Lenny Dang(Millennium Engineering and Integration (United States))
Cited by 72
Related Papers
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores
|Nature Cell Biology|2005|292